Unveiling Qiagen (QGEN) Q1 Outlook: Wall Street Estimates for Key Metrics

24.04.24 15:15 Uhr

Werte in diesem Artikel
Aktien

40,92 EUR -0,36 EUR -0,87%

Indizes

PKT PKT

18.630,9 PKT 260,9 PKT 1,42%

7.157,5 PKT 98,2 PKT 1,39%

2.975,3 PKT 0,8 PKT 0,03%

2.143,9 PKT 0,6 PKT 0,03%

187,1 PKT 1,2 PKT 0,65%

518,1 PKT 6,4 PKT 1,24%

9.916,5 PKT 131,8 PKT 1,35%

18.648,0 PKT 259,0 PKT 1,41%

18.618,7 PKT 254,7 PKT 1,39%

3.455,9 PKT 23,2 PKT 0,68%

7.332,9 PKT 100,5 PKT 1,39%

3.461,6 PKT 33,0 PKT 0,96%

2.536,8 PKT 23,0 PKT 0,92%

3.925,8 PKT 32,1 PKT 0,82%

Wall Street analysts forecast that Qiagen (QGEN) will report quarterly earnings of $0.44 per share in its upcoming release, pointing to a year-over-year decline of 17%. It is anticipated that revenues will amount to $454.97 million, exhibiting a decline of 6.3% compared to the year-ago quarter.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.With that in mind, let's delve into the average projections of some Qiagen metrics that are commonly tracked and projected by analysts on Wall Street.According to the collective judgment of analysts, 'Sales by Product Groups- Diagnostic solutions- NeuMoDx' should come in at $11.44 million. The estimate indicates a change of -12% from the prior-year quarter.The consensus estimate for 'Sales by Product Groups- Genomics / NGS' stands at $50.95 million. The estimate indicates a change of -7.4% from the prior-year quarter.The average prediction of analysts places 'Sales by Product Groups- PCR / Nucleic acid amplification' at $70.87 million. The estimate indicates a change of -8% from the prior-year quarter.Based on the collective assessment of analysts, 'Sales by Product Groups- Other' should arrive at $11.67 million. The estimate suggests a change of -31.4% year over year.It is projected by analysts that the 'Sales by Product Groups- Diagnostic solutions- QIAstat-Dx' will reach $23.82 million. The estimate indicates a change of +13.4% from the prior-year quarter.Analysts' assessment points toward 'Sales by Product Groups- Sample technologies' reaching $146.53 million. The estimate points to a change of -15.3% from the year-ago quarter.Analysts expect 'Sales by Product Groups- Diagnostic solutions' to come in at $174.25 million. The estimate points to a change of +6.9% from the year-ago quarter.Analysts forecast 'Sales by Product Groups- Diagnostic solutions- QuantiFERON' to reach $105.61 million. The estimate points to a change of +14.8% from the year-ago quarter.Analysts predict that the 'Revenue- Molecular Diagnostics' will reach $247.55 million. The estimate suggests a change of -1% year over year.View all Key Company Metrics for Qiagen here>>>Over the past month, shares of Qiagen have returned -1.9% versus the Zacks S&P 500 composite's -3% change. Currently, QGEN carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Highest Returns for Any Asset ClassIt’s not even close. Despite ups and downs, Bitcoin has been more profitable for investors than any other decentralized, borderless form of money.No guarantees for the future, but in the past three presidential election years, Bitcoin’s returns were as follows: 2012 +272.4%, 2016 +161.1%, and 2020 +302.8%. Zacks predicts another significant surge in months to come.Hurry, Download Special Report – It’s FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report QIAGEN N.V. (QGEN): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf QIAGEN

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf QIAGEN

NameHebelKOEmittent
NameHebelKOEmittent
Werbung

Quelle: Zacks

Nachrichten zu QIAGEN N.V.

Analysen zu QIAGEN N.V.

DatumRatingAnalyst
21.05.2024QIAGEN BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
02.05.2024QIAGEN NeutralUBS AG
02.05.2024QIAGEN NeutralUBS AG
30.04.2024QIAGEN BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
30.04.2024QIAGEN BuyDeutsche Bank AG
DatumRatingAnalyst
21.05.2024QIAGEN BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
30.04.2024QIAGEN BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
30.04.2024QIAGEN BuyDeutsche Bank AG
16.04.2024QIAGEN BuyDeutsche Bank AG
16.02.2024QIAGEN BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
DatumRatingAnalyst
02.05.2024QIAGEN NeutralUBS AG
02.05.2024QIAGEN NeutralUBS AG
30.04.2024QIAGEN NeutralUBS AG
30.04.2024QIAGEN HoldJefferies & Company Inc.
01.03.2024QIAGEN NeutralUBS AG
DatumRatingAnalyst
17.02.2021QIAGEN VerkaufenIndependent Research GmbH
14.12.2020QIAGEN VerkaufenDZ BANK
10.12.2020QIAGEN VerkaufenIndependent Research GmbH
24.11.2020QIAGEN VerkaufenIndependent Research GmbH
11.11.2020QIAGEN VerkaufenDZ BANK

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für QIAGEN N.V. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"